National Health (Pharmaceutical Benefits) Regulations (Amendment) (Cth)

STATUTORY RULES

1970 No.

________

REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953-1969.*

WHEREAS it is provided by sub-section (4.) of section 101 of the National Health Act 1953-1969 that a drug or medicinal preparation that was not a pharmaceutical benefit under the National Health Act 1953-1958 immediately before the commencement of that sub-section shall not be prescribed as a pharmaceutical benefit in accordance with section 85 of that Act unless the Pharmaceutical Benefits Advisory Committee has recommended to the Minister that it be so prescribed:

AND WHEREAS that Committee has recommended to the Minister that the following additional drugs and medicinal preparations be prescribed as pharmaceutical benefits under section 85 of the National Health Act 1953-1969, namely, the drugs and medicinal preparations inserted in the Third Schedule to the National Health (Pharmaceutical Benefits) Regulations by regulation 4 and the Third Schedule to these Regulations:

NOW THEREFORE I, THE GOVERNOR-GENERAL in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953-1969.

Dated this twentieth day of March, 1970.

Paul Hasluck

Governor-General.

By His Excellency’s Command,

(Sgd.) A. J. Forbes.

Minister of State for Health.

_________

Amendments of the National Health (Pharmaceutical Benefits) Regulations 

Commencement.

1. These Regulations shall come into operation on the first day of April, 1970.

First Schedule.

2. The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the First Schedule to these Regulations.

Second Schedule.

3. The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the Second Schedule to these Regulations.

Third Schedule.

4. The Third Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the Third Schedule to these Regulations.

Fourth Schedule.

5. The Fourth Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—

(a)by adding at the end of item 15 the letters “ , B.P.C.”;

(b)by omitting items 18 and 19; and

(c) by adding at the end of item 22 the letters “ , B.P.”.

_________________________________________________________________________

* Notified in the Commonwealth Gazette on 1970.

  Statutory Rules 1960, No. 17, as amended by Statutory Rules 1960, Nos. 90 and 102; 1961, Nos. 59 and 137; 1962, Nos. 34, 101 and 114; 1963, Nos. 34, 69 and 107; 1964, Nos. 12, 57 and 135; 1965, Nos. 51, 151 and 152; 1966, Nos. 80 and 144; 1967, Nos. 67, 116 and 158; 1968, Nos. 44, 76, 88 and 146; and 1969, Nos. 44, 107 and 185.

12752/70—Price 25c 10/13.3.1970

Fifth Schedule.

6.The Fifth Schedule to the National Health (Pharmaceutical Benefits) Regulations is repealed and the following Schedule is inserted in its stead:—

FIFTH SCHEDULE  Regulation 14.

Pharmaceutical Benefits the Prescribing of Which is Subject to Conditions and Restrictions

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
1	Acetylcholine Chloride with Mannitol, B.P.	Any disease or condition in a patient receiving treatment in or at an approved hospital
2	Acetylcysteine ............................................	Cystic Fibrosis (mucoviscidosis)
3	(1) Aspirin Tablets, B.P. ...........................	Any disease or condition in a pensioner
(2) Soluble Aspirin Tablets, B.P.
(3) Aspirin with Paracetamol and Caffeine Tablets
(4) Aspirin with Codeine Phosphate and Pentobarbitone Sodium Tablets
4	Acrylic Resin ..............................................	Ileostomy or colostomy conditions
5	Albumaid XP ..............................................	With the written authority of the Director-General, Phenylketonuria
6	Aldosterone .................................................	With the written authority of the Director-General, treatment of an acute crisis in—
Adrenal cortical hypofunction (including Addison’s disease and salt-losing congenital adrenal hypoplasia)
7	Allopurinol ..................................................	Crystalluria due to uric acid
Gout associated with renal failure or nephrolithiasis
Chronic gout not responding to other agents
Ankylosing spondylitis
8	Aloxiprin ......................................................	Osteoarthritis
Psoriatic arthropathy
Rheumatoid arthritis
9	Alprenolol Injection ...................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
10	Alprenolol Tablet .......................................	With the written authority of the Director-General, Idiopathic hypertrophic subaortic stenosis
Ankylosing spondilitis
11	Aluminium Acetylsalicylate Tablet	Osteoarthritis
Psoriatic arthropathy
Rheumatoid arthritis
12	Ambenonium Chloride ..............................	Myasthenia gravis
13	Aminocaproic Acid ....................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
14	Aminosalicylic Acid ..................................	Tuberculosis
15	(1) Amitriptyline Hydrochloride .............	Any disease or condition in a pensioner
(2) Amitriptyline Tablets, B.P.	The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Amitriptyline Hydrochloride or Amitriptyline Tablets, B.P.
With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
16	Amphotericin B Injection .........................	Systemic mycoses
17	(1) Amphotericin B Tablets ......................	Moniliasis
(2) Amphotericin B Lozenge
(3)Amphotericin B Suspension

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
18	(1) Ampicillin Capsules, B.P.....................	Infections of the ear or respiratory tract where they cannot be safely and effectively treated with sulphonamides, phenoxymethylpenicillin or phenethicillin
(2) Ampicillin Injections, Tablets and Suspension
Gram-negative infections where ampicillin appears to be the most suitable drug
Any bacterial infection of the genito-urinary tract which cannot be safely or effectively treated with sulphonamides
Broad spectrum antibiotic treatment of patients undergoing steroid therapy or recently subjected to steroid therapy
Pancreatitis, meningitis, any infection in pregnant women or in children where these cannot be safely and effectively treated with sulphonamides, phenoxymethyl-penicillin or phenethicillin
19	Angiotensin Amide ....................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
20	Ascorbic Acid Tablets, B.P.......................	Any disease or condition in a pensioner
21	Azathioprine ................................................	With the written authority of the Director-General, azathioprine therapy for a person who has been discharged from an approved hospital and received that therapy while a patient in the hospital
22	Beclamide ....................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
23	Benzathine Penicillin, B.P.........................	Prophylaxis of recurrent streptococcal infections, (including rheumatic fever)
24	Benzoin Compound Tincture, B.P.C. aerosol spray	Ileostomy or colostomy conditions
25	Benzylpenicillin Injection, 5,000,000 units	Bacterial endocarditis or septicaemia
26	(1) Benzylpenicillin Tablets, B.P.	Prophylaxis of recurrent streptococcal infections, (including rheumatic fever)
(2) Benzylpenicillin Capsules
27	Benzylpenicillin Injection, 10,000,000 units	Bacterial endocarditis or septicaemia
Gastrointestinal surgery
28	(1) Benzylpenicillin with Streptomycin Sulphate	Endocarditis due to Streptococcus faccalis or Streptococcus viridans
(2) Benzylpenicillin with Procaine Penicillin and Streptomycin Sulphate
29	Betahistine Hydrochloride ........................	Meniere’s Syndrome
30	(1) Betamethasone Acetate and Betamethasone Injection...........................	Intra-articular use
With the written authority of the Director-General,
(2) Betamethasone Sodium Phosphate Injection, B.P.	Pre-operative and post-operative prophylactic therapy for those patients undergoing or recently subjected to steroid therapy
31	Betamethasone Valerate with Clioquinol	For the treatment of diseases of the ear
32	Buclosamide with Salicylic Acid ............	For the treatment of diseases of the ear
33	Buclosamide, Salicylic Acid and Hydrocortisone Acetate	For the treatment of diseases of the car
34	Busulphan Tablets, B.P..............................	Treatment in malignant neoplasia
35	(1) Calciferol Tablets, Strong, B.P...........	Any disease or condition in a pensioner
(2) Calciferol, B.P.......................................	With the written authority of the Director-General—
Hypoparathyroidism
Osteomalacia following gastrectomy
Vitamin D-resistant rickets
36	Calcium Aminosalicylate .........................	Tuberculosis
37	Capreomycin Sulphate ..............................	Any disease or condition in a patient receiving treatment in or at an approved hospital
38	Carbamazepine ...........................................	Epilepsy
Trigeminal neuralgia

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
39	Carbenicillin ...............................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
40	(1) Carbenoxolone Sodium .....................	Any disease or condition in a patient receiving treatment in or at an approved hospital
(2) Cephaloridine ......................................
41	Charcoal Tablets .......................................	Ileostomy or colostomy conditions
42	Chlorambucil Tablets, B.P.......................	Treatment in malignant neoplasia
43	Chloramine Deodorant Tablets and Powder	Ileostomy or colostomy conditions
44	(1) Chloramphenicol Capsules, B.P.	Bacterial meningitis
(2) Chloramphenicol Injections	Intraocular infectious
(3) Chloramphenicol Oral Suspension	Rickettsioses
	Typhoid
The treatment of other serious infections in a patient where it is established by appropriate bacteriological testing that Chloramphenicol is the only suitable antibiotic listed as a pharmaceutical benefit, for use in treating the infection in the patient
45	Chlorotrianisene Tablets ..........................	Carcinoma of the prostate
46	(1) Chlorpromazine Hydrochloride, B.P.	Any disease or condition in a pensioner
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, B.P., Chlorpromazine Injection, B.P., or Chlorpromazine Tablets, B.P.
	(2) Chlorpromazine Injection, B.P.
	(3) Chlorpromazine Tablets, B.P.
With the written authority of the Director-General—
Hereditary chorea (Huntington’s)
Malignant neoplasia (late stage)
Radiation sickness
The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
47	Clofibrate ...................................................	With the written authority of the Director-General—
Diabetic retinopathy (exudative)
Hypercholesterolaemia with xanthomata
Hypercholesterolaemia, familial (essential)
48	(1) Cloxacillin Sodium, B.P.....................	Any disease or condition in a patient receiving treatment in or at an approved hospital
(2) Cloxacillin Capsules, B.P.
49	(1) Codeine Phosphate with Aspirin Soluble Tablets	Any disease or condition in a pensioner
(2) Codeine Phosphate with Aspirin Tablets
(3) Codeine Phosphate with Aspirin and Paracetamol Soluble Tablets
(4) Codeine Phosphate with Aspirin and Paracetamol Tablets
(5) Codeine Phosphate with Aspirin, Paracetamol and Caffeine Tablets
50	Cod Liver Oil Emulsion ..........................	Any disease or condition in a child under the age of twelve years or in a pensioner
51	Colistin Sulphomethate Sodium, B.P., for injection	Pyocyaneus infection, other Gram-negative infections where no other drug is effective
52	(1) Corticotrophin Injection, B.P.	With the written authority of the Director-General—
(2) Corticotrophin Gelatin Injection, B.P.	The prevention of side effects of corticosteroid therapy
(3) Corticotrophin Zinc Hydroxide Injection, B.P.

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whoso treatment it may be prescribed) for supply under Part VII. of the Act
52—	(1) Corticotrophin Injection, B.P.	Acquired haemolytic anaemia
contd	(2) Corticotrophin Gelatin Injection, B.P.	Acute disseminated encephalomyelitis
Acute exacerbations of multiple sclerosis
(3) Corticotrophin Zinc Hydroxide Injection, B.P.	Acute exacerbations of multiple sclerosis
	Acute exfoliative dermatitis
Acute phase of Bell’s Palsy
Acute rheumatic carditis
Addison’s disease or other forms of adrenocortical hypoplasia
Adrenogenital syndrome
Agranulocytosis
Behcet’s syndrome
Cranial arteritis
Cushing’s syndrome including hyperadrenocorticalism
Dermatomyositis
Encephalomyelitis
Giant cell thyroiditis proven by biopsy
Guillain-Barré syndrome
Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
Hansen’s disease
Hepatitis, progressive or continuing, proven by biopsy or biochemistry
Hodgkin’s disease
Hypoplastic anaemia
Hypsarrhythmia
Idiopathic hypercalcaemia
Inflammatory conditions of the uveal tract and retina
Keratoplasty
Leucine sensitive hypoglycaemia
Leukaemia
Lymphosarcoma and follicular lymphoma
Metastatic breast cancer
Mycosis fungoides
Nephrosis or nephrotic syndrome
Neuromyelitis optica
Optic neuritis following removal of tumors of the brain
Panhypopituitarism
Pemphigus
Periarteritis
Progressive transverse myelitis
Pseudohermaphroditism
Pulmonary eosinophilia
Purpura, Henoch’s
Regional ileitis (Crohn’s disease)
Reticulum cell sarcoma
Salaam convulsions
Sarcoidosis
Scleroderma
Severe reactions of the skin and mucosa following X-ray therapy
Splenic neutropenia
Status asthmaticus
Steroid therapy prior to operation for those patients under steroid therapy
Stevens-Johnson syndrome
Still’s disease in children under the age of sixteen years
Systemic lupus erythematosus
Sympathetic ophthalmitis

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
52—	Temporal arteritis
contd	Thrombocytopenic purpura
Tropical and non-tropical sprue and forms of malabsorption associated with those diseases
Type II nephritis
Ulcerative colitis proven by sigmoidoscopy or radiological report
53	Cortisone Injection, B.P.............................	With the written authority of the Director-General—
Acute exophthalmic ophthalmoplegia
Acute heart block complicating myocardial infarction
Anaemia, acquired haemolytic
Addison’s disease
Adrenocortical hypoplasia
Adrenogenital syndrome
Agranulocytosis
Angioneurotic oedema
Behcet’s syndrome
Benign intracranial hypertension
Cerebral tumours and cerebral oedema
Cranial arteritis
Cushing’s syndrome, including hyperadrenocorticalism
Dermatitis, acute exfoliative
Dermatitis herpetiformis
Dermatomyositis
Encephalitis
Encephalomyelitis
Encephalomyelitis, acute disseminated
Giant cell thyroiditis proven by biopsy
Guillain-Barré syndrome
Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
Hansen’s disease
Hepatitis, progressive or continuing, proven by biopsy or biochemistry
Hodgkin’s disease
Hypoplastic anaemia
Idiopathic hypercalcaemia
Inflammatory conditions of the uveal tract and retina
Interstitial keratitis due to syphilis or vernal conjunctivitis
Keratoplasty
Leucine sensitive hypoglycaemia
Leukaemia
Lymphosarcoma and follicular lymphoma
Meningitis
Metastatic breast cancer
Mycosis fungoides
Nephrosis or nephrotic syndrome
Neuromyelitis optica
Oedema of the spinal cord following trauma or infection
Optic neuritis following removal of tumors of the brain
Panhypopituitarism
Pemphigus
Periarteritis
Progressive transverse myelitis
Pseudohermaphroditism
Pulmonary eosinophilia

Purpura, Henoch’s

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
53—contd	Cortisone Injection, B.P.............................	Purpura, thrombocytopenic
	Regional ileitis (Crohn’s disease)
Reticulum cell sarcoma
Retroperitoneal fibrosis
Rheumatic carditis, acute
Sarcoidosis
Scleroderma
Severe reactions of the skin and mucosa following X-ray therapy
Splenic neutropenia
Status asthmaticus
Steroid therapy prior to operation in patients under steroid therapy
Stevens-Johnson syndrome
Still’s disease in a child under the age of sixteen years
Sneddon and Wilkinson’s sub-corneal pustular dermatosis
Sympathetic ophthalmitis
Systemic lupus erythematosus
Temporal arteritis
Total adrenalectomy
Treatment of malignancy in conjunction with radiotherapy or chemotherapy
Tropical and non-tropical sprue and all forms of malabsorption associated with those diseases
Type II nephritis
Ulcerative colitis proven by sigmoidoscopy or radiological report
54	Cyanocobalamin Injection, B.P................	Pernicious anaemia and other proven Vitamin B-12 deficiencies
Post gastrectomy treatment
Sub-acute combined degeneration of the cord
Neuroblastoma
55	(1) Cycloserine Tablets, B.P.....................	Any disease or condition in a patient receiving treatment in or at an approved hospital
(2) Cycloserine Capsules, B.P.
58	Cymogran ....................................................	With the written authority of the Director-General, phenylketonuria
57	(1) Cyproheptadine Hydrochloride, B.P.		Allergic rhinitis
(2) Cyproheptadine Tablets, B.P.	Allergic dermatoses
58	Cytosine Arabinoside Hydrochloride	Any disease or condition in a patient receiving treatment in or at an approved hospital
59	(1) Deodorant Detergent Solution (Terric N.8 with Spearmint Oil and Cetrimide)	Ileostomy or colostomy conditions
(2) Deodorant Detergent Solution (Lauryldimethyl Benzyl Ammonium Chloride and Terric N.8)
60	(1) Deoxycortone Aqueous Injections	Adrenal cortical hypofunction including Addison’s disease
(2) Deoxycortone Acetate Injection, B.P.	Total adrenalectomy
(3) Deoxycortone Trimethylacetate Injection, B.P.
(4) Deoxycortone Acetate Implants, B.P.
(5) Deoxycortone Acetate Tablets
61	Desferrioxamine .........................................	Any disease or condition in a patient receiving treatment in or at an approved hospital

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
62	Dexamethasone Sodium Phosphate Injections	Intra-articular use
Cerebral oedema
63	(1) Dextromoramide Tablets, B.P.	Treatment in malignant neoplasia
(2) Dextromoramide Tartrate, B.P.
64	Diazepam Injection ....................................	Electrical conversion of cardiac arrythmias (cardioversion)
Endoscopy
Epilepsy
Minor operative procedures
Upper motor neurone lesion
Premedication induction of anaesthesia
65	Diazepam Syrup and 10 mg. Tablet	Epilepsy
Upper motor neurone lesion
66	Diazepam Tablets 2 mg. and 5 mg	Epilepsy
Upper motor neurone lesion
Multiple sclerosis
Stiff-man syndrome
67	Dicyclomine Hydrochloride with Doxylamine Succinate and Pyridoxine Hydrochloride	Vomiting in pregnancy
68	Dienoestrol Cream .....................................	Any disease or condition in a pensioner
69	Diethanolamine Fusidate, B.P.C.	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Diethanolamine Fusidate is the only appropriate antibiotic that is listed as a benefit
70	Dihydroergotoxine Mesylate ....................	For the treatment of patients who have suffered an attack of paralytic poliomyelitis
(1) Tablets
(2) Injections
71	Dihydrotachysterol .....................................	Hypoparathyroidism
72	Diloxanide Furoate Tablets, B.P...............	Intestinal amoebiasis
73	Dimethicone Aerosol Spray......................	Ileostomy or colostomy conditions
74	Dimethicone Creams .................................	Use with surgical appliances
75	Dioetyl Sodium Sulphosuccinate with Danthron	Any disease or condition in a pensioner
76	Disodium Cromoglycate ...........................	With the written authority of the Director-General—
The prevention of asthma for a patient who is under 18 years of age, whose attacks of asthma have been sufficiently severe and frequent to interfere seriously with his normal activities of life and whose re-occurrences of asthma could not be controlled by adequate use of bronchodilaters and other standard means of prevention and treatment
The prevention of asthma for a patient whose attacks of asthma have been sufficiently severe and frequent to interfere seriously with his normal activities of life and to require the continuous use of over 7.5 mg. of prednisone, or its equivalent, daily or who suffers from a disease indicating that corticosteroid therapy should not be applied, such as peptic ulcer, hypertension of 180/100 or more before treatment, diabetes, osteoporosis proven by X-ray or steroid induced myopathy
77	Disodium Stilboestrol Diphosphate	Carcinoma of the prostate
78	Ditophal .......................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
79	Droperidol ...................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
80	(1) Erythromycin Estolate Capsules B.P.	Amoebiasis
		Brucellosis
(2) Erythromycin Estolate, B.P.	Leptospirosis

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
80—contd	(3) Erythromycin Tablets, B.P.	Lymphogranuloma venereum
	(4) Erythromycin Ethyl Succinate	Pneumonia due to mycoplasma pneumoniae
(5) Erythromycin Glucoheptonate	Psittacosis
(6) Erythromycin Lactobionate	Rickettsioses
(7) Erythromycin Stearate, B.P.	Staphylococcal septicaemia or staphylococcal pneumonia
(8) Erythromycin Stearate Tablets, B.P.	Actinomycosis, Trachoma, or any bacterial or spirochaetal infections where these cannot be safely and effectively treated with sulphonamides, phenoxymethylpenicillin or phenethicillin
81	Ethacrynic Acid .........................................	Fluid retention associated with heart failure, cirrhosis of the liver or nephrotic syndrome
Fluid retention associated with other conditions and not responding to thiazides
82	Ethinyloestradiol Tablets, B.P..................	Any disease or condition in a pensioner
Carcinoma of the prostate
Hereditary telangiectasis
Menopause, premature; surgically induced
Turner’s syndrome
83	Ethionamide ...............................................	Tuberculosis
84	Ethisterone Tablets, B.P............................	Turner’s syndrome
85	Ethyloestrenol ............................................	With the written authority of the Director-General—
Intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long term treatment with corticosteroids
Osteomalacia following gastrectomy
86	Fludrocortisone Tablets, B.P....................	Adrenal cortical hypoplasia including Addison’s disease
Total adrenalectomy
87	Flufenamic Acid ........................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
88	Flumethasone Pivalate and Clioquinol	For the treatment of diseases of the ear
89	Fluorouracil Sodium .................................	Treatment in malignant neoplasia
90	Fluoxymesterone Tablets, B.P ................	Eunuchism
Carcinoma of the breast
With the written authority of the Director-General—
Intermittent use for corticosteroid-induced osteoporosis
Proven aplastic anemias
91	Fluphenazine Enanthate ...........................	The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits—
Fluphenazine Enanthate
Fluphenazine Hydrochloride
With the written authority of the Director-General—
Hereditary chorea (Huntington’s)
Malignant neoplasia (late stage)
Radiation sickness
The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
92	Fluphenazine Hydrochloride ...................	Any disease or condition in a pensioner
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
92—contd	discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits—
Fluphenazine Enanthate
Fluphenazine Hydrochloride
With the written authority of the Director-General—
Hereditary chorea (Huntington’s)
Malignant neoplasia (late stage)
Radiation sickness
The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
93	(1) Folic Acid, B.P.....................................	Proven folic acid deficiency
(2) Folic Acid Tablets, B.P. 5 mg.	Sprue or the sprue-like syndrome
94	Folic Acid Tablets, B.P. 1 mg..................	Pregnancy
95	Folinic Acid ...............................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
96	Framycetin Sulphate Tablets ..................	Bowel sterilization preparatory to major surgery
97	Frusemide Tablets, B.P.............................	Fluid retention associated with heart failure, cirrhosis of the liver or nephrotic syndrome
Fluid retention associated with other conditions and not responding to thiazides
98	Galactomin Formula No. 17 ...................	With the written authority of the Director-General—
Galactosaemia
Conditions needing an extreme restriction of lactose in the patient’s diet, under the age of four years
99	Galactomin Formula No. 19 ...................	With the written authority of the Director-General, Glucose-galactose malabsorption
100	Gentamicin Sulphate ................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
101	Glucose Indicator—Blood ......................	With the written authority of the Director-General, Diabetes mellitus in which adequate control is impossible by any other means because of low renal threshold
102	Goat’s Milk, Dehydrated .........................	With the written authority of the Director-General, cow’s milk allergy in children under the age of four years
103	Goat’s Milk, Whole (Sterilised) .............	With the written authority of the Director-General, cow’s milk allergy in children under the age of four years
104	Griseofulvin Tablets, B.P.........................	With the written authority of the Director-General, for use in severe tinea infections due to Microsporum, Trichophyton or Epidermophyton species which have been proven by laboratory examination or Wood’s Light
105	Guanacline Tablets ...................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
106	Halibut Liver Oil Capsules .....................	Any disease or condition in a pensioner
107	Haloperidol ................................................	Any disease or condition in a pensioner
The treatment of a mental disorder in a person who has after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Haloperidol
With the written authority of the Director-General—
Hereditary chorea (Huntington’s)
Malignant neoplasia (late stage)

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
107—	Radiation sickness
contd	The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
108	(1) Hexachlorophane with Chloroxylenol	Any disease or condition in a patient receiving treatment in or at an approved hospital
(2) Hexachlorophane with Entsufon
(3) Hexachlorophane with Lissapol
(4) Hexachlorophane in Soap Solution
109	Hydrocortisone Injection .........................	With the written authority of the Director-General—
Acquired haemolytic anaemia
Acute disseminated encephalomyelitis
Acute exfoliative dermatitis
Acute exophthalmic ophthalmoplegia
Acute heart block complicating myocardial infarction
Acute rheumatic carditis
Addison’s disease or other forms of adrenocortical hypoplasia
Adrenogenital syndrome
Agranulocytosis
Angioneurotic oedema
Behcet’s syndrome
Benign intracranial hypertension
Cerebral oedema
Cerebral tumors
Cranial arteritis
Cushing’s syndrome including hyperadrenocorticalism
Dermatitis herpetiformis
Dermatomyositis
Encephalitis
Encephalomyelitis
Giant cell thyroiditis proven by biopsy
Guillain-Barré syndrome
Hamman-Rich syndrome diffuse interstitial pulmonary fibrosis
Hansen’s disease
Hepatitis, progressive or continuing, proven by biopsy or biochemistry
Hodgkin’s disease
Hypoplastic anaemia
Idiopathic hypercalcaemia
Inflammatory conditions of the uveal tract and retina
Interstitial keratitis due to syphilis or vernal conjunctivitis
Keratoplasty
Leucine sensitive hypoglycaemia
Leukaemia
Lymphosarcoma and follicular lymphoma
Malignancy treatment in conjunction with radiotherapy or chemotherapy
Meningitis
Metastatic breast cancer
Mycosis fungoides
Nephrosis or nephrotic syndrome

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
109—contd	Hydrocortisone injection ..........................	Neuromyelitis optica
Oedema of the spinal cord following trauma or infections
Optic neuritis following removal of tumors of the brain
Panhypopituitarism
Pemphigus
Periarteritis
Progressive transverse myelitis
Pseudohermaphroditism
Pulmonary eosinophilia
Purpura, Henoch’s
Regional ileitis (Crohn’s disease)
Reticulum cell sarcoma
Retroperitoneal fibrosis
Sarcoidosis
Scleroderma
Severe reactions of the skin and mucosa following X-ray therapy
Sneddon and Wilkinson’s sub-corneal pustular dermatosis
Splenic neutropenia
Status asthmaticus
Steriod therapy prior to operation for those patients under steroid therapy
Stevens-Johnson syndrome
Still’s disease in children under the age of sixteen years
Sympathetic ophthalmitis
Systemic lupus erythematosus
Temporal arteritis
Thrombocytopenic purpura
Total adrenalectomy
Tropical and non-tropical sprue and forms of malabsorption associated with these diseases
Type II nephritis
Ulcerative colitis proven by sigmoidoscopy or radiological report
110	Hydrocortisone Acetate Injection, B.P.	Intra-articular use
111	Hydrocortisone Acetate, B.P. with Neomycin Sulphate, B.P. Ear drops and ear ointment	For the treatment of diseases of the ear
112	Hydrocortisone with 1,2-Propanediol Diacetate and Acetic Acid	For the treatment of diseases of the ear
113	Hydrocortisone Sodium Succinate Injection	Acute adrenal cortical hypofunction due to medical or surgical crisis
Prophylactic therapy before, during and after surgical procedures for patients undergoing or recently subjected to steroid therapy
Stevens-Johnson disease
114	Hydrocortisone Ear Drops .......................	For the treatment of diseases of the ear
115	Hydroxocobalamin Injection, B.P.	Pernicious anaemia and other proven Vitamin B-12 deficiencies
Post gastrectomy treatment
Sub-acute combined degeneration of the cord
Neuroblastoma
116	Hydroxyprogesterone Caproate ..............	Carcinoma of the endometrium
Progesterone deficiency proved by hormonal assay, by lateral wall smear or by endometrial biopsy
117	Idoxuridine .................................................

Infectious caused by Herpes Simplex Virus

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
118	(1) Imipramine Tablets, B.P....................	Any disease or condition in a pensioner
(2) Imipramine Hydrochloride, B.P.	The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Imipramine Hydrochloride, B.P. or Imipramine Tablets, B.P.
With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
119	Indomethacin Capsules ...........................	Acute gout
Ankylosing spondylitis
Leontiasis osseum
Osteoarthritis not responding to salicylates
Psoriatic arthropathy
Reiter’s syndrome
Rheumatoid arthritis not responding to salicylates
120	Indomethacin Suppositories ...................	For the treatment of the following conditions in persons who cannot tolerate oral indomethacin—
Acute gout
Ankylosing spondylitis
Leontiasis osseum
Osteoarthritis not responding to salicylates
Psoriatic arthropathy
Reiter’s syndrome
Rheumatoid arthritis not responding to salicylates
121	Influenza Vaccine .....................................	For prophylaxis of pensioners only
122	Insect Allergen Extract—Honey Bee	For the treatment of severe constitutional reaction to bee stings
123	Isoniazid Tablets, B.P...............................	Tuberculosis
124	Isoprenaline Hydrochloride Tablets, 30 mg.	Stokes-Adams syndrome
125	Kanamycin Sulphate Capsules, Injections and Oral Solution	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Kanamycin Sulphate is the most appropriate antibiotic
126	Kitasamycin ...............................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
127	Levorphanol Tartrate ...............................	Obstetrical use
Severe intractable pain
128	Lignocaine Injection, B.P.........................	Cardiac arrhythmias
129	Lincomycin Hydrochloride......................	Gram positive coccal infections where these cannot be safely and effectively treated with penicillin and where resistance to erythromycin has been established by laboratory investigation
Osteomyelitis
130	Liothyronine Tablets, B.P.........................	Myxoedema
131	Lofenalac ...................................................	With the written authority of the Director-General, phenylketonuria
132	Lypressin Nasal Spray .............................	Diabetes insipidus
133	Maphenide Acetate ...................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
134	Medroxyprogesterone Acetate Tablets, 2.5 mg.	Carcinoma of the endometrium
135	Medroxyprogesterone Acetate Tablets, 10 mg.	Carcinoma of the endometrium
		Precocious puberty
136	Medroxyprogesterone Acetate Tablets, 100 mg.	Carcinoma of the breast
		Carcinoma of the endometrium
Hypernephroma

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
137	Medroxyprogesterone Acetate Injections	Carcinoma of the endometrium
		Hypernephroma
Progesterone deficiency proven by hormonal assay, by lateral wall smear or by endometrial biopsy
138	Melphalan ..................................................	Treatment in malignant neoplasia
139	Mercaptopurine Tablets, B.P...................	Allergic granulomatous angiitis
Lupus erythematosus
Nephrotic syndrome
Periarteritis (Nodosa)
Treatment in malignant neoplasia
140	(1) Methandienone Tablets, B.P.	With the written authority of the Director-General—
(2) Methenolone Acetate	Intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long-term treatment with corticosteroids
141	Methicillin Sodium, B.P. for Injection	Proven or suspected staphylococcal septicaemia
142	Methotrexate Tablets ...............................	Treatment in malignant neoplasia
143	Methotrexate Injections ...........................	Any disease or condition in a patient receiving treatment in or at an approved hospital
144	Methylprednisolone Acetate Injection	Intra-articular use
145	(1) Methyltestosterone Tablets, B.P.	Carcinoma of the breast
Eunuchism
(2) Methyltestosterone, B.P.	Klinefelter’s syndrome (seminiferous tubule dysgenesis)
146	Methysergide Maleate .............................	With the written authority of the Director-General, migraine, severe recalcitrant when other treatment has failed
147	Metyrapone ................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
148	Minafen ......................................................	With the written authority of the Director-General, phenylketonuria
149	Morphine Sulphate, B.P. with Tacrine Tablets	Severe intractable pain
150	Mustine Hydrochloride Injection	Treatment in malignant neoplasia
151	Nalidixic Acid ...........................................	Urinary tract infections where positive bacteriological evidence shows sulphonamides to be ineffective
152	Nandrolone Decanoate ............................	Carcinoma of the breast
With the written authority of the Director-General—
Intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long-term treatment with corticosteroids
Severe osteoporosis due to proven pancreatitis
153	Nandrolone Hexoxyphenyl Propionate	Carcinoma of the breast
With the written authority of the Director-General—
Intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long-term treatment with corticosteroids
154	Nandrolone Phenylpropionate Injection, B.P.	Carcinoma of the breast
		With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
155	(1) Natamycin Oral Tablets ....................	Moniliasis
(2) Natamycin Oral Suspension
156	Neomycin Sulphate Powder ....................	With the written authority of the Director-General, use by inhalation in cystic fibrosis (mucoviscidosis)
157	Neomycin Sulphate, B.P. with Gramicidin, Thonzonium Bromide, Thonzylamine Hydrochloride and Hydrocortisone	For the treatment of diseases of the ear
Acetate, B.P.

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
158	Neomycin Tablets, B.P.............................	Bowel sterilization preparatory to major surgery
Encephalopathy, hepatic
159	Neomycin Undecenoate with Bacitracin Zinc	For the treatment of diseases of the ear
160	Nicotinic Acid Tablets, B.P......................	Any disease or condition in a pensioner
161	Nitrazepam .................................................	Myoclonic epilepsy
162	(1) Nitrofurantoin Tablets, B.P................	Urinary tract infections where positive bacteriological evidence shows sulphonamides to be ineffective
(2) Nitrofurantoin Oral Suspension
163	Nitromin .....................................................	Treatment in malignant neoplasia
164	Norethisterone Acetate, B.P.....................	Carcinoma of the breast
165	(1) Nortriptyline Hydrochloride, B.P.	Any disease or condition in a pensioner
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Nortriptyline Hydrochloride, B.P., Nortriptyline Tablets, B.P. or Nortriptyline Capsules, B.P.
	(2) Nortriptyline Tablets, B.P.
	(3) Nortriptyline Capsules, B.P.
With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
166	Nutramigen ................................................	With the written authority of the Director-General—
Cow’s milk allergy in children under the age of four years
Cystic Fibrosis (mucoviscidosis)
Galactosaemia
Lactose intolerance
167	Nystatin Tablets, B.P.................................	Moniliasis
168	Orciprenaline Sulphate Injection	Any disease or condition in a patient receiving treatment in or at an approved hospital
169	Oxprenolol Tablet .....................................	With the written authority of the Director-General, idiopathic hypertrophic subaortic stenosis
170	Oxprenolol Injection ................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
171	Oxycodone Pectinate ................................	Treatment in malignant neoplasia
172	Oxymetholone ...........................................	With the written authority of the Director-General, Proven aplastic or hypoplastic anaemias (familial)
173	(1) Pancreatin, B.P.....................................	Cystic Fibrosis (mucoviscidosis)
(2) Pancreatin Enzyme 4 X	Following pancreatico—duodenectomy
U.S.N.F. XII	Pancreatic steatorrhoea
(3) Pancrelipase
174	(1) Paracetamol Suspension ....................	Any disease or condition in a pensioner
(2) Paracetamol Tablets, B.P.
175	Paracetamol with Codeine Phosphate and Pentobarbitone Sodium	Any disease or condition in a pensioner
176	(1) Paraffin Liquid Emulsion ..................	Any disease or condition in a pensioner
(2) Paraffin Liquid Emulsion with Phenolphthalein
177	Pargyline Hydrochloride .........................	Any disease or condition in a patient receiving treatment in or at an approved hospital
178	Penicillamine .............................................	With the written authority of the Director-General—
Acute heavy metal intoxication
Cystinosis
Cystinuria with calculus formation
Haemoglobinuria, paroxysmal cold
Wilson’s disease (hepatolenticular degeneration)
179	Pethidine Hydrochloride with Levallorphan Tartrate	Obstetric use

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
180	(1.) Phenylbutazone Tablets, B.P.	Acute Gout
(2) Phenylbutazone Capsules	Ankylosing spondylitis
Osteoarthritis not responding to salicylates
Psoriatic arthropathy
Reiter’s syndrome
Rheumatoid arthritis not responding to salicylates
181	(1) Phenylbutazone Suppositories	For the treatment of the following conditions in persons who cannot tolerate oral Phenylbutazone—
(2) Phenylbutazone Injection
Acute gout
Ankylosing spondylitis
Osteoarthritis not responding to salicylates
Psoriatic arthropathy
Reiter’s syndrome
Rheumatoid arthritis not responding to salicylates
182	Phytomenadione Injection, B.P............	Antidote to anticoagulants
183	Phytomenadione Injection, B.P. ..1 mg.	Antidote to anticoagulants
Suspected cerebral trauma of the new born
Haemorrhagic disease of the new born
184	Pituitary, Posterior Lobe, Insufflation	Diabetes insipidus
185	Plasma Substitute (Polypeptide)...........	Any disease or condition in a patient receiving treatment in or at an approved hospital
186	Polymyxin B. Sulphate Powder............	With the written authority of the Director-General, use by inhalation in cystic fibrosis (mucoviscidosis)
187	Polymyxin B. Sulphate Neomycin Sulphate and Hydrocortisone	For the treatment of diseases of the ear
188	Polymyxin B. Sulphate with Bacitracin and Neomycin Sulphate Ear drops	For the treatment of diseases of the ear
189	Polymyxin B. Sulphate with Lignocaine Hydrochloride and Propylene Glycol	For the treatment of diseases of the ear
190	Polyoestradiol Phosphate......................	Carcinoma of the breast
Carcinoma of the prostate
191	Prednisolone Sodium Phosphate Retention Enema and Suppository	With the written authority of the Director-General—
Ulcerative colitis proven by sigmoidoscopy or radiological report
Proctitis proven by sygmoidoscopy
192	(1) Prednisolone Acetate Injection	Intra-articular use
(2) Prednisolone Butyl Acetate Injection
193	Prednisolone Sodium Phosphate and Neomycin Sulphate	For the treatment of diseases of the ear
194	Prednisolone Sodium Succinate Injection	Acute adrenal cortical hypofunction due to any medical or surgical crises
Prophylactic therapy before, during and after surgical procedures for patients undergoing or recently subjected to steroid therapy
Stevens-Johnson disease
195	Procarbazine Hydrochloride..................	Treatment in malignant neoplasia
196	(1) Prochlorperazine...............................	Meniere’s Syndrome
(2) Prochlorperazine Tablets, B.P........
197	Progesterone.............................................	Progesterone deficiency proven by hormonal assay, by lateral wall smear or by endometrial biopsy
198	Propranolol Injection, B.P.....................		Any disease or condition in a patient receiving treatment in or at an approved hospital
199	Propranolol Tablets, B.P........................	With the written authority of the Director-General, idiopathic hypertrophic subaortic stenosis
200	Prosobee....................................................	With the written authority of the Director-General—
Galactosaemia
Homocystinuria

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
200—contd	Lactose intolerance
	Milk allergy in children under the age of four years
201	Protriplyline Hydrochloride.....................	Any disease or condition in a pensioner
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Protriptyline Hydrochloride
With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
202	Pyrazinamide..............................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
203	(1) Pyridostigmine Injection, B.P............	Myasthenia gravis
(2) Pyridostigmine Tablets, B.P..............
204	Pyridoxine Hydrochloride Tablets	Homocystinuria
Radiation sickness
Treatment and prophylaxis of peripheral neuritis caused or likely to be caused by isoniazid therapy
205	Pyrimethamine Tablets.............................	Toxoplasmosis
Malaria
206	(1) Riboflavine Tablets.............................	Any disease or condition in a pensioner
(2) Senna Fruit Extract (standardised)
207	Sobee............................................................	With the written authority of the Director-General—
Galactosaemia
Homocystinuria
Lactose intolerance
Milk allergy in children under the age of four years
208	(1) Sodium Aminosalicylate Tablets, B.P.	Tuberculosis
(2) Sodium Aminosalicylate Injection
(3) Sodium Aminosalicylate Cachets
(4) Sodium Aminosalicylate Granules
(5) Sodium Aminosalicylate with Isoniazid, B.P.
209	Sodium Folate............................................	Proven folic acid deficiency
Sprue or the sprue-like syndrome
210	Sodium Fusidate........................................	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Sodium Fusidate is the only appropriate antibiotic that is listed as a benefit
211	Soyalac........................................................	With the written authority of the Director-General—
Galactosaemia
Homocystinuria
Lactose intolerance
Milk allergy in children under the age of four years
212	Spiramycin..................................................	Staphylococcal septicaemia or staphylococcal pneumonia
Toxoplasmosis, active-serologically proven
Any gram-positive bacterial infections where these cannot be treated safely and effectively by sulphonamides or penicillins
213	Spironolactone Tablets, B.P.....................	With the written authority of the Director-General—
To supplement other diuretics when these have

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
213—contd	proved inadequate
	Myasthenia gravis
214	Stanolone...................................................	Carcinoma of the breast
With the written authority of the Director-General—
Intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long-term treatment with corticosteroids
215	Stanozolol..................................................	With the written authority of the Director-General—
Intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long-term treatment with corticosteroids

216	Streptokinase............................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
217	Sulphasalazine..........................................	Ulcerative colitis
218	Sulthiame...................................................	For use where other anticonvulsants have failed
219	(1) Surgical Cement................................	Ileostomy or colostomy conditions
(2) Surgical Cement Solvent	For use with surgical appliances
220	(1) Sustanon..............................................	Eunuchism
(2) Testosterone Implants, B.P.	Klinefelter’s syndrome (seminiferous tubule dysgenesis)
(3) Testosterone Enanthate
(4) Testosterone Propionate Injection, B.P.	Carcinoma of the breast
221	Tetanus Antitoxin, B.P. (Bovine)	Patients who have previously received an injection of equine serum
222	Tetracosactrin Injection Set 250 mg. and 2 ml. solution	Any disease or condition in a patient receiving treatment in or at an approved hospital
223	Tetracosactrin Injections—	With the written authority of the Director-General—
1 mg. in 1 ml.............................................	The prevention of side effects of corticosteroid therapy
2 mg. in 2 ml.............................................
Acquired haemolytic anaemia
Acute disseminated encephalomyelitis
Acute exacerbations of multiple sclerosis
Acute exfoliative dermatitis
Acute phase of Bell’s Palsy
Acute rheumatic carditis
Addison’s disease or other forms of adrenocortical hypoplasia
Adrenogenital syndrome
Agranulocytosis
Behcet’s syndrome
Cranial arteritis
Cushing’s syndrome including hyperadrenocorticalism
Dermatomyositis
Encephalomyelitis
Giant cell thyroiditis proven by biopsy
Guillain-Barré syndrome
Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
Hansen’s disease
Hepatitis, progressive or continuing, proven by biopsy or biochemistry
Hodgkin’s disease
Hypoplastic anaemia
Hypsarrhythmia
Idiopathic hypercalcaemia
Inflammatory conditions of the uveal tract and retina
Keratoplasty
Leucine sensitive hypoglycaemia
Leukaemia

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
223—contd	Tetracosactrin Injections—	Lymphosarcoma and follicular lymphoma
	1 mg. in 1 ml.	Metastatic breast cancer
2 mg. in 2 ml.	Mycosis fungoides
Nephrosis or nephrotic syndrome
Neuromyelitis optica
Optic neuritis following removal of tumors of the brain
Panhypopituitarism
Pemphigus
Periarteritis
Progressive transverse myelitis
Pseudohermaphroditism
Pulmonary eosinophilia
Purpura, Henoch’s
Regional ileitis (Crohn’s disease)
Reticulum cell sarcoma
Salaam convulsions
Sarcoidosis
Scleroderma
Severe reactions of the skin and mucosa following X-ray therapy
Splenic neutropenia
Status asthmaticus
Steroid therapy prior to operation for those patients under steroid therapy
Stevens-Johnson syndrome
Still’s disease in children under the age of sixteen years
Systemic lupus erythematosus
Sympathetic ophthalmitis
Temporal arteritis
Thrombocytopenic purpura
Tropical and non-tropical sprue and forms of malabsorption associated with those diseases
Type II nephritis
Ulcerative colitis proven by sigmoidoscopy or radiological report
224	(1) Thiambutosine Tablets, B.P..............	Leprosy
(2) Thiambutosine Injection
225	Thiamine Hydrochloride Tablets, B.P.	Any disease or condition in a pensioner
226	Thiethylperazine Tablets and Suppositories	Radiation sickness
Nausea resulting from cytotoxic therapy
227	(1) Thioridazine Tablets, B.P..................	Any disease or condition in a pensioner
(2) Thioridazine	The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits—
Thioridazine
Thioridazine Tablets, B.P.
With the written authority of the Director-General—
Hereditary chorea (Huntington’s)
Malignant neoplasia (late stage)
Radiation sickness
The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
228	Thyrotrophin..............................................	Any disease or condition in a patient receiving treatment in or at an approved hospital

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
229	Tragacanth, Indian (Gum Karaya)	Ileostomy or colostomy conditions
230	.......................................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
231	Tretamine....................................................	Treatment in malignant neoplasia
232	Triacetyloleandomycin.............................	Amoebiasis
Brucellosis
Leptospirosis
Lymphogranuloma venereum
Pneumonia due to mycoplasma pneumoniae
Pneumonia, staphylococcal
Psittacosis
Rickettsioses
Staphylococcal septicaemia
Actinomycosis, Trachoma, or any bacterial or spirochaetal infections where these cannot be safely and effectively treated by sulphonamides, phenoxymethylpenicillin or phenethicillin
233	(1) Trifluoperazine Tablets, B.P..............	Any disease or condition in a pensioner
(2) Trifluoperazine Hydrochloride, B.P.	The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Trifluoperazine Hydrochloride, B.P. or Trifluoperazine Tablets, B.P.
With the written authority of the Director-General—
Hereditary chorea (Huntington’s)
Malignant neoplasia (late stage)
Radiation sickness
The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
234	Triglyde........................................................	With the written authority of the Director-General, proven malabsorption
235	Trimetaphan Injection, B.P......................	Hypotensive in anaesthesia
236	Trimethoprim with Sulphamethoxazole	Any disease or condition in a patient receiving treatment in or at an approved hospital
237	Vadrine........................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
238	Velactin........................................................	With the written authority of the Director-General—
Galactosaemia
Homocystinuria
Lactose intolerance
Milk allergy in children under the age of four years
239	(1) Vinblastine Sulphate...........................	Treatment in malignant neoplasia
(2) Vincristine Sulphate
240	Vinyl Pyrrolidone and Vinyl Acetate with Benzocaine Aerosol Spray	Ileostomy or colostomy conditions
241	(1) Viomycin Sulphate.............................	Tuberculosis
(2) Viomycin Sulphate Injection, B.P.
242	Vitamin A with Thiamine Hydrochloride, Riboflavine, Nicotinamide, Ascorbic Acid and Vitamin D Tablets and Capsules	Any disease or condition in a pensioner

THE SCHEDULES

FIRST SCHEDULE  Regulation 2.

Amendments of the First Schedule to the National Health (Pharmaceutical Benefits) Regulations

1. After item 4 insert—

“ 4a. Alcohol (95%) ”.

2. After item 6 insert—

“ 6a. Amethocaine Hydrochloride ”.

3. After item 16 insert—

“ 16a. Arachis Oil ”.

4. After item 23 insert—

“ 23a. Bendrofluazide ”.

5. After item 37 insert—

“ 37a. Camphor ”.

6. After item 52 insert—

“ 52a. Chloroform ”.

7. After item 73 insert—

“ 73a. Concentrated Peppermint Water ”.

8. After item 76 insert—

“ 76a. Cottonseed Oil ”.

9. After item 103 insert—

“ 103a. Dextrose

103b. Dextrose Monohydrate ”.

10. After item 115 insert—

“ 115a. Dilute Alcohols ”.

11. After item 135 insert—

“ 135a. Ether Anaesthetic ”.

12. After item 143 insert—

“ 143a. Eucalyptus Oil ”.

13. After item 187 insert—

“ 187aa. Industrial Methylated Spirit ”.

14. After item 199 insert—

“ 199a. Laevulose ”.

15. After item 210 insert—

“ 210a. Maize Oil ”.

16. After item 222 insert—

“ 222a. Mepyramine Maleate

222b. Mepyramine Tablets ”.

17. After item 240 insert—

“ 240a. Methylprednisolone Tablets ”.

18. After item 273 insert—

“ 273a. Olive Oil ”.

19. After item 291 insert—

“ 291a. Peppermint Oil ”.

20. Omit item 321.

21. Omit item 356.

22. Omit items 386 to 388 (inclusive), insert—

“ 386. Sulphadimethoxine

386a. Sulphadimidine Injection

387. Sulphadimidine Sodium

388. Sulphamethizole ”.

23. After item 427 insert—

“ 427a. Turpentine Oi l”.

_________

SECOND SCHEDULE Regulation 3.

Amendments of the Second Schedule to the National Health (Pharmaceutical

 Benefits) Regulations

1. Omit from item 8 “ Amino Acids with Sorbitol and Ethanol ” (in the third column), insert—

“ Amino Acids with Sorbitol and Alcohol ”.

2. Omit item 30.

3. After item 63 insert—

“ 63a

Dihydrocodeine Acid Tartrate...........

— ”.

4. Omit item 97.

5. Omit item 104.

6. Omit item 117.

7. After item 149 insert—

“ 149a	Pentobarbitone.................................	Barbitone Sodium
Phenobarbitone Sodium
Pentobarbitone ”.

8. After item 174 insert—

“ 174a

Sodium Acid Citrate.........................

— ”.

9. After item 177 insert—

“ 177a	Sorbitol............................................	Amino Acids with Sorbitol
Amino Acids with Sorbitol and Alcohol ”.

10. Insert in item 186 “ Trimethoprim with Sulphamethoxazole ” (in third column).

11. Omit from item 184 “ Streptomycin Sulphate with Sulphaguanidine B.P.C.” (in the third column).

12. After item 201 insert—

“ 201a

Tiemonium Iodide............................

— ”.

13. After item 207 insert—

“ 207a Trimethoprim................................... Trimethoprim with Sulphamethoxazole ”.

14. Omit item 209, insert—

“ 209	Vinyl Acetate...................................	Vinyl Pyrrolidone and
Vinyl Acetate with Benzocaine
209a	Vinyl Pyrrolidone.............................	Vinyl Acetate and
Vinyl Pyrrolidone with Benzocaine ”.

15. Omit item 213.

———

THIRD SCHEDULE Regulation 4.

Amendments of the Third Schedule to the National Health (Pharmaceutical Benefits) Regulations

1. After item 25 insert—

“ 25a. Ambenonium Chloride ”.

2. Omit item 48.

3. Omit item 56.

4. Omit item 79.

5. Omit item 89.

6. Omit item 93.

7. Omit item 115.

8. After item 127 insert—

“ 127a. Dihydrocodeine Acid Tartrate ”.

9. Omit item 135.

10. After item 138a insert—

“ 138b. Droperidol ”.

11. Omit item 155.

12. After item 173 insert—

“ 173a. Glibenclamide ”.

13. Omit item 187.

14. After item 196a. insert—

“ 196b. Injection of Amino Acids with Sorbitol and Alcohol

196c. Injection of Casein Hydrolysate with Laevulose and Alcohol

196d. Injection of Casein Hydrolysate and Dextrose

196e. Injection of Dextran with Dextrose

196f. Injection of Potassium Chloride with Sodium Lactate and Dextrose

196g. Injection of Sodium Chloride with Potassium Chloride, Calcium Chloride and Dextrose

196h. Injection of Sodium Chloride with Sodium Lactate and Dextrose ”.

15. Omit item 207

16. After item 223 insert—

“ 223a. Maphenide Acetate ”.

17. Omit item 235.

18. After item 266 insert—

“ 266a. Oxprenolol ”.

19. After item 285 insert—

“ 285a. Pentazocine Lactate ”.

20. After item 286 insert—

“ 286a. Pentobarbitone

286b. Peritoneal Dialysis Solution with Dextrose ”.

21. After item 328 insert—

“ 328a. Rauwolfia Serpentina, B.P.C.”.

22. After item 345 insert—

“ 345a. Sodium Lactate Compound Injection B.P. with Dextrose ”.

23. Omit item 350.

24. After item 384 insert—

“ 384a. Thiabendazole ”.

25. Omit item 405, insert—

“ 405. Trimethoprim ”.

26. Omit item 414.

27. After item 417 insert—

“ 417a. Vinyl Acetate

417b. Vinyl Pyrrolidone ”.

28. Omit item 419a.

                    

Printed by Authority by the Government Printer of the Commonwealth of Australia